pSivida VP of Research to Discuss Company's Protein and Antibody Sustained Delivery System at 5th Oc
pSivida VP of Research to Discuss Company's Protein and Antibody Sustained Delivery System at 5thOcular Diseases and Drug Development Conference
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that the Company's Vice President of Research, Dr. Hong Guo, will present a paper at the 5th Ocular Diseases and Drug Development Conference in San Francisco on March 21. Dr. Guo's presentation will take place at 10:30 a.m.
Dr. Guo's presentation entitled "Sustained delivery of proteins and anti-bodies" is expected to discuss recent developments in pSivida's Tethadur technology.
"One of the many challenges to the pharmaceutical industry is to develop effective delivery systems for protein and antibody drugs," said Dr. Paul Ashton, President and CEO of pSivida. "Dr. Guo will describe results we have had with our proprietary Tethadur system, which is based on bioerodible, nanostructured, porous silicon. With the large number of biologic patents expiring and the development of the Bio-similar field, improved protein delivery will become increasingly important."
pSivida has previously announced a technology evaluation agreement with a leading global biopharmaceutical company investigating the use of this technology in ophthalmology.
The Ocular Diseases and Drug Development Conference promotes the discovery of ocular disease development by bringing together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases. Among those participating are representatives from most of the pharmaceutical companies that are involved in the development of treatments for these conditions.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drugs delivery products designed to release drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. Two FDA-approved products, Vitrasert™ and Retisert™ are licensed to Bausch & Lomb. The company has licensed ILUVIEN® for DME to Alimera Sciences and that product has received marketing authorization in Austria, France, Germany, Portugal, Spain and the UK. pSivida has clinical trials ongoing for the treatment of posterior uveitis and glaucoma and ocular hypertension. Other technologies under development by pSivida include protein and antibody delivery systems in early clinical stages.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: Alimera's ability to finance, achieve additional marketing approvals, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's resubmission of its NDA for ILUVIEN for DME and its ability to obtain regulatory approval for, and if approved, to finance, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the U.S.; financing and success of Phase III posterior uveitis trials including efficacy, side effects and risk/benefit profile of the posterior uveitis micro-insert; initiation, financing and success of Latanoprost Product Phase II trials and exercise by Pfizer of its option; development of products using Tethadur and BioSilicon; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; adverse side effects; ability to attain profitability; ability to obtain additional capital; further impairment of intangible assets; fluctuations in operating results; decline in royalty revenues; ability to, and to find partners to, develop and market products; termination of license agreements; competition and other developments affecting sales of products; market acceptance; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; possible influence by Pfizer; absence of dividends; and other factors described in our filings with the SEC. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
Martin E. Janis & Company, Inc.
Beverly Jedynak, President
312-943-1123; 773-350-5793 (cell)
Brian Leedman, Vice President, Investor Relations
+61 (0) 41 228 1780
KEYWORDS: United States North America Massachusetts
The article pSivida VP of Research to Discuss Company's Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.